Descartes-08

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Systemic Lupus Erythematosus (SLE)

Conditions

Systemic Lupus Erythematosus (SLE)

Trial Timeline

Feb 12, 2024 → Nov 1, 2026

NCT ID

NCT06038474

About Descartes-08

Descartes-08 is a phase 2 stage product being developed by Cartesian Therapeutics for Systemic Lupus Erythematosus (SLE). The current trial status is active. This product is registered under clinical trial identifier NCT06038474. Target conditions include Systemic Lupus Erythematosus (SLE).

What happened to similar drugs?

10 of 20 similar drugs in Systemic Lupus Erythematosus (SLE) were approved

Approved (10) Terminated (4) Active (7)

✅Baricitinib + CyclophosphamideEli LillyApproved

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅EfalizumabMerckApproved

✅AmbrisentanGilead SciencesApproved

✅BMS-986165Bristol Myers SquibbApproved

✅versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07391605	Phase 2	Recruiting	Mar 1, 2026	May 1, 2027	Antisynthetase Syndrome
NCT07089121	Phase 1/2	Recruiting	Jan 1, 2026	Dec 1, 2026	Childhood-onset Systemic Lupus Erythematous
NCT06038474	Phase 2	Active	Feb 12, 2024	Nov 1, 2026	Systemic Lupus Erythematosus (SLE)
NCT04146051	Phase 2	Active	Dec 4, 2019	Mar 31, 2026	Myasthenia Gravis, Generalized

Competing Products

20 competing products in Systemic Lupus Erythematosus (SLE)

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	26
Micafungin	Astellas Pharma	Phase 2	35
E6742	Eisai	Phase 1/2	32
KHK4827	Kyowa Kirin	Phase 1	29
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Cyclophosphamide	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29